Secondary Offering for Immuron Limited

(Est. Date 06/09/2017)

Immuron is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies that Immuron believes can address significant unmet medical needs. Immunomodulator polyclonol antibodies are blood proteins that are produced by the immune system to attack foreign substances such as bacteria and can be specifically utilized to increase and/or decrease the activity of the immune system. Immuron's oral polyclonal antibodies offer targeted delivery within the gastrointestinal (GI) track but do not cross into the bloodstream. Immuron believes that its two lead immunomodulator product candidates, IMM-124E and IMM-529, have the potential to transform the existing treatment paradigms for NASH (Non Alcoholic Steatohepatitis) and for Clostridium difficile (C. difficile), respectively. Immuron also markets an OTC product, Travelan, has been designated by the Therapeutic Goods Administration ("TGA") in Australia and Health Canada as being preventative to Traveler's Diarrhea . Travelan is also based on the same technology.

Show More
This information has been gathered from the company's offering prospectus.

Secondary Offering Documentation


Key Secondary Offering Data

Joseph Gunnar & Co.
This information has been gathered from the company's offering prospectus.

How Does a Secondary Offering Work?

Open a Motif Account

Open a brokerage account to get ready for trading.

Participate in an Offering

Review secondary offering pricing, prospectus, and other documentation.

Place a Conditional Order

Select an investment amount and fund the secondary offering.

Receive Your Offering Shares

View your allocated shares on account positions page.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.